Cellectis (NASDAQ: CLLS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 21.43 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $12.03 million which missed the analyst consensus estimate of $14.61 million by 17.65 percent. This is a 85.12 percent increase over sales of $6.50 million the same period last year.